Search

OBJECTIVE:To investigate the psychometric properties of the Body Uneasiness Test (BUT) in a large sample of subjects with obesity seeking treatment. BUT is a 71-item self-report questionnaire in two parts: BUT-A which measures weight phobia, body image concerns, avoidance, compulsive self-monitoring, detachment and estrangement feelings towards one’s own body (depersonalization); and BUT-B, which looks at specific worries about particular body parts or functions. METHODS:We recruited a clinical sample of 1,812 adult subjects (age range 18–65 years, females 1,411, males 401) with obesity (Body Mass Index, BMI ≧30 kg/m2) and a normal weight (BMI value between 18.5 and 25 kg/m2) non-clinical sample of 457 adult subjects (females 248, males 209) with an Eating Attitudes Test-26 (EAT-26) score under the cut-off point 20 (scores ≧20 indicate possible cases of eating disorders). RESULTS:The exploratory and confirmatory analyses confirmed a structural five-factor model for BUT-A and an eight-factor model for BUT-B. Internal consistency was satisfactory. Concurrent validity with Binge Eating Scale (BES) and Three-Factor Eating Questionnaire (TFEQ) was evaluated. The authors calculated mean values for BUT scores in adult (18–65 years) patients with obesity, and evaluated the influence of gender, age and BMI. Females obtained statistically significant higher scores than males in all age groups and in all classes of obesity; patients with obesity, compared with normal weight subjects, generally obtained statistically significant higher scores, but few differences could be attributed to the influence of BMI. CONCLUSION:The BUT can be a valuable multidimensional tool for the clinical assessment of body uneasiness in obesity; the scores of its sub-scales do not show a linear correlation with BMI values.

Extracts of the skin of some amphibians from Australia and Papua New Guinea contained, in addition to the usual 5-hydroxyindolealkylamines and histamine: a. two new, hitherto unknown indolealkylamines, i.e . O-sulphate of bufotenidine and 2-(3-indolyl)ethyltrimethylammonium, a quaternary ammonium base of tryptamine. The rare O-sulphate of bufotenine was also present, the occurrence of which had previously been demonstrated only in the skin of some South American toads; b. a series of uncommon imidazolealkylamines, such as N′-acetylhistamine, N′-methyl-histamine, N′,N′-dimethylhistamine, spinaceamine and 6-methylspinaceamine. It appears evident that amphibian skin continues to be an exceptionally rich source of aromatic amines.

The synthesis and the antiprolactin activity of a group of 8-acetylergolines are reported.

No relevant conflicts of interest to declare.

Background and aims.Essential thrombocythemia (ET) rarely occurs in children and adolescents. In our experience, 40% of pediatric patients with primary thrombocythemia (PT) have JAK2 V617F or CALR mutations, 24% have a diagnosis of ET without any known molecular markers while 36% have hereditary thrombocytosis (HT) with a MPLS505A mutation. Thrombotic events, frequent in adult ET presenting high-risk factors and rare in pediatric PT, have been observed in pediatric HT patients with MPLS505A mutation in treatment with aspirin (ASA). The multidrug resistance protein-4 (MRP4) is an ATP-binding cassette transporter involved in the efflux of several pharmacological and physiological compounds. MRP4 has been identified as a modulator of ASA action in platelets; in addition, it also influences platelet activation. Recent studies have shown that MRP4 over-expression has a role in reducing the effect of ASA in patients who have undergone a bypass surgical procedure and that ASA induces platelet MRP4 upregulation. Aims of this study were to evaluate and correlate MRP4 expression and platelet function in children and adolescents aged <20 years at diagnosis with different subtypes of PT.

Fifteen N‐acylureas of dihydrolysergic acid derivatives are prepared by treatment of the acids with carbodiimides or by the two‐step procedure given in the scheme.

Ergoline compounds are capable of binding to adrenergic, dopaminergic and serotoninergic receptors.